Forecast the next resistance mutation like the weather
Flu vaccines are chosen by predicting which virus strains will dominate next season. The same forecasting maths could predict which resistance mutation a patient's tumour will develop next.
Evolutionary forecasting methods from influenza and bacterial resistance estimate the fitness of circulating variants from their frequency trajectories. Applied to longitudinal ctDNA and to population-level databases of resistance under each drug, they could give per-patient probabilities of specific next-step mechanisms. Forecasts would be scored prospectively, as in weather forecasting, to build calibrated models.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- AI that is built but not validated or deployed · Thousands of cancer AI models are published; a handful are in clinical use, and fewer have shown they help patients.
Pages like this
not linked directly; found by shared links- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Drug resistance (primary and acquired), Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.
- IdeaAutonomous closed-loop adaptive therapy driven by blood tests and evolutionary models
Shares Drug resistance (primary and acquired), Osimertinib, AI that is built but not validated or deployed, Acquired resistance to every therapy.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaSlow the tumour's mutation engine with APOBEC inhibitors during targeted therapy
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.
- IdeaFund a biopsy at progression, every time, as standard care
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaA clone report from blood at every treatment cycle
Shares Osimertinib, Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaAn open atlas of collateral sensitivity for every approved targeted drug
Shares Drug resistance (primary and acquired), Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.
- IdeaFind the parts of a tumour the drug never reaches
Shares Drug resistance (primary and acquired), Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy.